Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arcese, W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arcese, W
Haematologica, Vol 91, Issue 2, 223-230
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

Unrelated cord blood transplants in adults with hematologic malignancies

W Arcese, V Rocha, M Labopin, G Sanz, AP Iori, M de Lima, A Sirvent, A Busca, S Asano, I Ionescu, P Wernet, E Gluckman, and

Eurocord-Netcord.

BACKGROUND AND OBJECTIVES: We analyzed outcomes and risk factors after unrelated cord blood transplantation (CBT) in adults with hematologic malignancies. DESIGN AND METHODS: One hundred and seventy-one patients were transplanted after 1997. Their median age was 29 years (15-55), and the median follow-up time was 18 months (1-71). Most patients had acute or chronic leukemia (n=142, 83%), 91 (53%) were transplanted in advanced phase and an autologous transplant had failed in 32 (19%). Most patients (87%) received an HLA-mismatched cord blood unit with 1-2 HLA disparities. At infusion, the median number of nucleated cells and CD34(+) cells was 2.1x10(7)/kg and 1x10(5)/kg, respectively RESULTS: The cumulative incidence of neutrophil recovery at day 60 was 72+/-3% with a median of 28 days (11-57). A higher neutrophil count and use of hematopoietic growth factors were independently associated with faster neutrophil recovery. The cumulative incidence of grade II-IV acute graft-versus-host disease was 32+/-4% and this complication was not associated with the number of HLA mismatches. The 2-year cumulative incidence of chronic graft-versus-host disease, transplant related-mortality and relapse were 36+/-10%, 51+/-4% and 22+/-4%, respectively. At 2-years, disease-free-survival for patients transplanted in early, intermediate and advanced phases of disease was 41+/-9%, 34+/-10% and 18+/-4%, respectively. In multivariate analyses, advanced disease status was an adverse factor for relapse and disease-free survival. INTERPRETATION AND CONCLUSIONS: Unrelated CBT is a clear alternative for adults with hematological malignancies lacking an HLA-matched related or unrelated donor. The choice of units containing a higher neutrophil count and a policy of earlier transplantation are likely to provide better results.


This article has been cited by other articles:


Home page
 haematolHome page
A. P. Iori, W. Arcese, F. Milano, E. Calabrese, G. F. Torelli, W. Barberi, M. G. Mascolo, L. De Felice, M. Screnci, B. Lucarelli, et al.
Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up
Haematologica, August 1, 2007; 92(8): 1051 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. N. Barker
Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors?
Hematology, January 1, 2007; 2007(1): 55 - 61.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
J.-L. Harousseau, S. Jagannath, P. G. Richardson, P. Sonneveld, M. W. Schuster, D.-L. Esseltine, and K. C. Anderson
Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications.
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 3543 - 3543.
[Abstract] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.